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ABSTRACT
Background: Chronic exertional compartment syndrome (CECS) is a condition in which
muscle tissue expands against the surrounding fascia during activity and is compressed
along with the nerves and blood vessels within the muscle compartment, leading to
abnormally high intracompartmental pressure (ICP) and debilitating pain. Treatment
typically includes fasciotomy, which results in significant levels of CECS recurrence;
however, botulinum toxin A (BoNT-A) injection has recently been seen to decrease both
ICP and pain through an unknown mechanism with little to no recurrence.
Methods: In this study, PyRosetta was used to model the probability of docking interaction
between BoNT-A light or heavy chain and enzymes cyclooxygenase-1 (COX-1),
cyclooxygenase-2 (COX-2), prostaglandin E2 receptor 4 (EP4), endothelial nitric oxide
synthase (eNOS), and inducible nitric oxide synthase (iNOS). Subsequently, myoblasts
(HSkM) were treated with BoNT-A and assayed based on PyRosetta predicted interactions.
Results: The EP4/BoNT-A heavy chain combination was found to have reaction scores
most comparable to known interactions of BoNT-A in neural cells. In accordance with this
finding, levels of cyclic adenosine monophosphate (cAMP), a downstream effector of EP4,
consistently increased in myoblasts treated with BoNT-A.
Conclusion: Altogether, these data uncover an area of future research in determining the
interaction of BoNT-A and the EP4 pathway in muscle cells, as well as the implications
this may have on CECS and its treatment.
Keywords: chronic exertional compartment syndrome, CECS, botulinum toxin A, BoNTA, Botox, prostaglandin E2 receptor 4, EP4, cyclooxygenase-1, COX-1, cyclooxygenase-
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2, COX-2, endothelial nitric oxide synthase, eNOS, inducible nitric oxide synthase, iNOS,
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INTRODUCTION
Chronic exertional compartment syndrome (CECS) is a condition in which
muscle tissue expands against the surrounding fascia during activity and is compressed
along with the nerves and blood vessels within the muscle compartment leading to
abnormally high intracompartmental pressure (ICP). Proposed causes of CECS include
ischemia, muscle hypertrophy, and fascial resistance or hypersensitivity, although the
triggers are unknown. This condition is characterized by debilitating pain and cramping
of the affected muscles during exercise that is relieved quickly with rest, and diagnosis is
based on occurrence of these symptoms and high ICP measurements shortly post-activity.
Typical treatment involves cessation of activity or fasciotomy, both of which have high
levels of CECS recurrence that vary significantly between various studies but are often
20-50% (Wuellner, et al., 2017).
REVIEW OF LITERATURE
BoNT-A as a Treatment for Chronic Exertional Compartment Syndrome
Botulinum toxin A (BoNT-A) has recently been demonstrated to reduce
symptoms of CECS and ICP levels when injected into the affected muscles, but the
mechanisms behind this treatment are not well understood. In one study, 15 out of 16
patients diagnosed with CECS and treated with BoNT-A had reduced pain and normal
ICP during activity 3 to 9 months post-injection. Proposed causes for symptom relief
include reduced release of acetylcholine (causing muscle atrophy), reduction of muscle
hypotonia, and/or induced muscle relaxation leading to increased blood flow to the
affected muscles (Isner-Horobeti, et al., 2013). Another case study demonstrated longlasting relief of severe CECS symptoms with BoNT-A injection, with ultrasound showing
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no signs of muscle atrophy or texture changes (Baria & Sellon, 2016). This challenges
previously accepted assumptions that ICP decrease is due to atrophy of the injected
muscles and indicates that another mechanism of BoNT-A is present, potentially at the
cellular, neural, or vascular level. Finally, a case study of CECS in the hand demonstrated
reduced ICP, full strength recovery, and decreased hypertrophy 15 months post-injection;
and the mechanisms of BoNT-A hypothesized were amyotrophy due to reduction of
acetylcholine (ACh) release, improved blood supply to limit muscle ischemia, and
analgesic action (Orta, et al., 2018). However, not all of these mechanisms would
decrease ICP, so the researchers suggested that these effects might be combined with
each other or work in addition to other mechanisms. Thus, the exact mechanisms of
BoNT-A on CECS symptom management remains unclear and highlights areas for
further research.
Mechanisms of Botulinum Toxin Type A
BoNT-A is most understood through its application at the neuromuscular
junction. In normal activity of the neuromuscular junction, muscle contraction is initiated
as synaptic vesicles filled with ACh are released via exocytosis across the nerve-muscle
synapse. In order for this to occur, synaptic vessels are loaded and docked onto the
presynaptic membrane, where they are primed by ATP so that they can undergo calciumregulated exocytosis. Soluble NSF (N-ethylmaleimide sensitive factor) attachment
protein (SNAP) receptors (SNAREs) are essential to transporting the vesicle membrane
near the plasma membrane, and dissociation of the SNARE complex by binding of
SNAPs and NSF is necessary for this process to be carried out (Dolly, 2003).
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When neural cells are treated with BoNT-A, the heavy chain of BoNT-A binds to
distinct G-protein coupled receptors (GPCRs) on the cell membrane. This allows the
toxin to enter the cytosol, where the SNAP-25 protein is cleaved by the light chain of
BoNT-A, which contains a selective, zinc-dependent protease. Therefore, the release of
ACh from peripheral nerves is inhibited. This blockage of ACh is typically long-lasting
and highly selective, and beneficial effects may last three to six months depending on the
condition being treated (Dolly, 2003). However, the effect of BoNT-A outside of the
neuromuscular junction is not well understood or researched, although other potential
applications include its antinociceptive and anti-inflammatory effects (Aoki, 2005;
Matak, et al., 2019). As discussed previously, researchers who have treated CECS with
BoNT-A have proposed interactions between BoNT-A and skeletal muscle at the cellular,
neural, or vascular levels. These interactions may replace or occur in addition to the
interaction at the neuromuscular junction (Baria & Sellon, 2016; Isner-Horobeti, et al.,
2013; Orta, et al., 2018).
Relevant Pathways and Receptors within Skeletal Muscle
Since BoNT-A interacts at the neuromuscular junction through a GPCR, it is
possible that BoNT-A may interact with other GPCRs present on skeletal muscle cells
and cause downstream effects or enter the cell and affect intracellular proteins. Many
prostaglandins (PGs), which are synthesized through the cyclooxygenase (COX)
pathway, as well as endothelial and inducible nitric oxide synthase (eNOS and iNOS,
respectively) are influenced by GPCRs and directly involved in relief and regulation of
the symptoms of CECS through regulation of blood flow, inflammation, muscle cell
expansion, and nociception (Liu, et al., 2016; Mortensen, González-Alonso, et al., 2007;
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Mortensen, Nyberg, et al., 2009; Sun & Ye, 2012). Prostaglandin E2 receptor 4 (EP4), in
particular, is a PG receptor and GPCR that can cause inflammation and be involved in
inflammatory diseases and responses, and it activates adenyl cyclase (AC) to upregulate
cyclic adenosine monophosphate (cAMP) within the cell. Increases in cAMP can lead to
hypertrophic responses of myofibers in skeletal muscle, an issue seen in patients with
CECS (Berdeaux & Stewart, 2012; Yokoyama, et al., 2013).
Additionally, novel studies of BoNT-A treatment on chronic visceral pain through
injection to peripheral organs have demonstrated inhibition of COX-2 and EP4
expression. When prostatitis was induced in rats, injection of BoNT-A led to an 89.4%
decrease of COX-2 expression in the prostate and a 90.5% decrease in the L6 spinal cord
(Chuang, et al., 2008). A similar study of BoNT-A injection after induced cystitis in rats
found that COX-2 expression was reduced by 77.8%, 61.7%, and 54.8% while EP4
expression was reduced by 56.8%, 26.9%, and 84.2% in the bladder, L6 spinal cord, and
S1 spinal cord, respectively. This indicates that BoNT-A inhibits COX-2 and EP4
expression in visceral organs and the L6 and S1 spinal cord and suppresses inflammation
and hyperactivity (Chuang, et al., 2009). Another study of BoNT-A treatment on human
myoblasts and fibroblasts in vitro demonstrated that BoNT-A modulated the cell cycle
and transcriptome within myoblasts through direct interactions between the toxin and
different cellular surface receptors, intracellular targets, and signaling pathways (Zanotti,
et al., 2018).
Altogether, these studies suggest it is reasonable to hypothesize that upregulation
of cAMP, EP4, COX-2 and similar proteins such as COX-1, iNOS, or eNOS could cause
symptoms of CECS and could therefore be modulated by direct BoNT-A treatment if
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BoNT-A can bind to surface protein receptors such as EP4 and inhibit further signaling
and activation of cAMP or intracellular proteins such as COX-1, COX-2, iNOS, or
eNOS.
Effects of BoNT-A on Human Skeletal Muscle Cells in vitro
Therefore, the present study aimed to determine if COX-1, COX-2, eNOS, iNOS,
or EP4 are likely to interact directly with BoNT-A, by creating and analyzing protein
models using protein-protein and protein-ligand docking programs from PyRosetta, a
computational chemistry program. These results indicated an interaction between BoNTA heavy chain and EP4, which was subsequently confirmed as levels of cAMP in human
skeletal muscle myoblasts increased after treatment with BoNT-A.
METHODS
Computational Analysis
In order to analyze probability of interaction between BoNT-A light chain (LC) or
heavy chain (HC) and COX-1, COX-2, eNOS, iNOS, or EP4, protein and ligand
structures were first obtained from the Protein Data Bank (PDB). The specific PDB IDs
used were 2IMC for BoNT-A LC (Silvaggi, et al. 2007), 2VUA for BoNT-A HC
(Stenmark, et al. 2008), 6Y3C for COX-1 (Miciaccia, et al., 2021), 5IKR for COX-2
(Orlando & Malkowski, 2016), 4D1O for eNOS (Li, et al., 2014), 2NSI for iNOS (Li, et
al.,1999), and 7D7M for EP4 (Nojima, et al., 2021). BoNT-A LC was combined with
COX-1, COX-2, iNOS, and eNOS based on their location within the cell cytoplasm and
the mechanism of BoNT-A LC within the cell, while BoNT-A HC was combined with
EP4 based on its location within the cell membrane and the mechanism of BoNT-A HC
to bind and allow entrance into the cell. BoNT-A LC was also combined with
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synaptosome associated protein 25 (SNAP25) (PDB ID: 3DDA; Kumaran, et al., 2008),
and BoNT-A HC was combined with ganglioside co-receptor GT1B (PDB ID: 2VU9;
Stenmark, et al., 2008). These combinations have known interactions in vivo, allowing
them to be used as control comparisons for output data. Using a virtual machine enabled
with PyRosetta (PyRosetta4.Release.python38.inux.release-275; Chadbury, et al., 2010)
and PyMOL (The PyMOL Molecular Graphics System, Version 2.0, n.d.), proteins were
combined into a joint file, cleaned from additional H2O or interfering ligand molecules,
and filled with any missing amino acid residues. Finally, joint files were run through
protein-protein (for all combinations including BoNT-A LC) or protein-ligand (for all
combinations including BoNT-A HC) docking programs from PyRosetta software.
Human Skeletal Myoblast Differentiation Culture
After thawing, human skeletal myoblasts (HSkM, Cat. no. A12555 & A11440;
Gibco) were differentiated in Dulbecco’s Modified Eagle Medium (Gibco) supplemented
with 2% horse serum (Gibco), plated on an untreated 24-well plate with a density of
240,000 cells per well, and incubated at 37 °C with 5% CO2. After 48 hours, HSkM cells
became elongated, indicating their differentiation was complete and allowing further
treatments to proceed.
Preparation of Botulinum Toxin A Dilutions
An original vial containing 100 IU of BoNT-A (Creative BioMart) was diluted
with 5 mL of bacteriostatic 0.9% sodium chloride solution (Hospira) to a concentration of
20 IU/mL. Then, a serial dilution in differentiation medium was made to produce
dilutions of 0, 0.24, 0.48, 1.2, 2.4, 4.8, 7.2, and 9.6 IU/mL, which corresponds to 0, 0.5,
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1, 2.5, 5, 10, 15, or 20 IU BoNT-A per 106 cells, based on the dilutions tested in previous
models (Zanotti et al., 2018).
Cytotoxic Assessment with DAPI and PI Fluorescence Assay
After differentiation, cells were treated in triplicate with 0.5 mL per well of either
0, 0.5, 1, 2.5, 5, 10, 15, or 20 IU per 106 cells, as prepared above. Cells were incubated at
37 °C with 5% CO2 for 24 hours, aspirated, stained with a solution containing 1 μL/1 mL
4’,6-diamidino-2-phenylindole (DAPI; ThermoFisher) and 1 μL/1 mL propidium iodide
(PI; ThermoFisher) in 1X PBS, and incubated for 10 minutes before aspirating and
washing twice with 1X PBS. Cells were imaged using a Nikon Ti-E Fluorescent
Microscope and counted using cell counting software to determine cytotoxicity of
treatments.
cAMP Direct Immunoassay
In order to investigate the effects of BoNT-A on EP4, the levels of cAMP in cells
with or without BoNT-A treatment were analyzed through the cAMP Direct
Immunoassay Kit (Colorimetric) (Cat. no. K371; BioVision). HSkM were differentiated,
treated with either 0 IU (control cells) or 1 IU BoNT-A per 106 cells diluted in
bacteriostatic 0.9% sodium chloride solution (Hospira) and differentiation medium as
prepared above for the cytotoxicity assay, and incubated at 37 °C with 5% CO2 for 24
hours. Medium was aspirated, and cells were treated with 50 μL of 0.1 M HCl per well
and incubated at room temperature. Cells were scraped, collected, and centrifuged, and
the supernatant was assayed directly. The standard cAMP curve and quantification of
cAMP in samples was achieved following the protocol included in the kit.

8
Statistical Analysis
Statistical analysis of cAMP concentration data was performed using an F-test
and Student’s t-test assuming equal variances on Microsoft Excel. Through these tests,
both one-tailed and two-tailed p-values were obtained and compared.
RESULTS
Computational Data Indicates HC-EP4 Interaction
Computational data outputs were received as total weighted scores measured in
Rosetta Energy Units (REU). These scores had values similar to exothermic and
endothermic reaction energy values – thus, more negative values indicated a more stable
and therefore more likely interaction between the molecules tested. Each combination
tested gave 3-6 scores based on different docking positions. Therefore, an average of
these values would not be relevant as each value represented a distinct position of
interaction, and only the most probable position of interaction should be considered. The
lowest value from each combination was compared in order to determine the most likely
interaction to be further tested. As seen in Fig. 1, the total weighted score of HC-EP4 was
most comparable to the controls, LC-SNAP25 and HC-GT1B, while other test
combinations were significantly different from the controls. The lowest values for control
combinations were -585.193 REU and -128.517 REU for LC-SNAP25 and HC-GT1B,
respectively, and the lowest value for test combinations was -677.325 REU for HC-EP4
(Table 1). Consequently, EP4 was chosen to be further investigated through its secondary
effector, cAMP, during in vitro testing.
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Table 1: Lowest total weighted scores are predicted by PyRosetta between BoNT-A and SNAP25, EP4,
and GT1B.

Docking Combination

Lowest Total Weighted Score (REU)

-log(REU)

LC-SNAP25

-847.419

2.928098

HC-EP4

-735.705

2.866704

HC-GT1B

-128.517

2.108961

LC-iNOS

74243.906

-4.87066

LC-eNOS

74866.516

-4.87429

LC-COX2

77261.938

-4.88797

LC-COX1

78015.531

-4.89218

4

Total Weighted Score [log(REU)]

3

2.928098

2.866704
2.108961

2
1
0

LC SNAP25

HC EP4

HC GT1B

LC iNOS

LC eNOS

LC COX2

LC COX1

-1
-2
-3
-4
-5
-6

-4.87066081 -4.87428762 -4.8879656 -4.89218107

Docking Combinations

Figure 1: Strong docking interactions are predicted by PyRosetta between BoNT-A and SNAP25, EP4,
and GT1B, but not iNOS, eNOS, COX2, or COX1. Combinations are between either BoNT-A light chain
(LC) or heavy chain (HC) and SNAP25, EP4, GT1B, iNOS, eNOS, COX2, or COX1 based on their
location within the cell. The lowest total weighted score was taken from each combination. If this score was
negative, the log of the absolute value was taken. For positive scores, the –log was taken. Therefore, in this
graph, a more positive score corresponds with a more probable docking position and interaction. Control
combinations are shown in purple, while test combinations are shown in blue.
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Cytotoxicity Assessment of HSkM Treated with BoNT-A
Cytotoxicity was determined through fluorescence microscope imaging, as seen in
Fig. 2. In Fig. 3, BoNT-A concentrations of 0-5 IU per 106 cells were seen to be most
consistent at causing minimal cytotoxicity, while concentrations of 10-20 IU per 106 cells
were more variable. Average cytotoxicity of cells treated with 1 IU BoNT-A was 0.997 ±
1.421%, while average cytotoxicity of cells treated with 20 IU BoNT-A was 80.5 ±
10.5%.

Figure 2: Cell viability of HSkM is not affected by 1 IU of BoNT-A. Fluorescence microscope imaging of
HSkM after BoNT-A with DAPI (blue) for viability, and PI (red) for cytotoxicity. Cell counting software
identified these colored spots to determine total cell count and total dead cell count.
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Figure 3: Cytotoxicity of BoNT-A treatment on HSkM myoblasts cells increases progressively with
concentration. Concentrations of 0, 0.5, 1, 2.5, 5, 10, 15, and 20 IU BoNT-A per 106 cells were incubated at
37 °C with 5% CO2 for 24 hours, aspirated, stained with DAPI and PI in 1X PBS, and incubated for 10
minutes before aspirating and washing with 1X PBS. Cells were imaged using a Nikon Ti-E Fluorescent
Microscope and counted to determine cytotoxicity of treatments. Results shown indicate the mean ±
standard deviation of cell death for each treatment.

cAMP Direct Immunoassay
PyRosetta’s predicted interaction between BoNT-A HC and EP4 was investigated
in vitro through activity assessment of cAMP, a secondary messenger of EP4. Based on
high cell viability, a treatment of 1 IU BoNT-A per 106 cells was selected for analysis
with the cAMP direct immunoassay. Control samples had cAMP concentrations of 3.498
fmol/well and 2.665 fmol/well for an average of 3.081 ± 0.589 fmol/well, while the two
wells containing samples treated with 1 IU BoNT-A had cAMP concentrations of 9.478
fmol/well and 6.522 fmol/well for an average of 8.000 ± 2.090 fmol/well, showing a
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consistent increase in cAMP (Fig. 4). In a two-sample F-test for variances, Fstat < Fcrit,
indicating that the variances were equal. According to the one-tail two-sample t-test
assuming equal variances, p = 0.04, indicating that cAMP concentration in cells treated
with 1 IU BoNT-A was significantly higher than cAMP concentration in control cells.
1 IU BoNT-A

Control

cAMP Standards

Linear (cAMP Standards)

1.8
1.6

OD 450 nm

1.4
1.2

y = -36.472x + 1.416
R² = 0.9129

1
0.8
0.6
0.4

0

0.005

0.01

0.015

0.02

0.025

cAMP (pmole)
Figure 4: Concentration of cAMP increases with BoNT-A treatment. cAMP standards were used to form a
standard curve and regression line. The equation of this line was used to determine cAMP concentration in
control and 1 IU BoNT-A treated cells based on OD 450 nm readings, and these data points are also
displayed. Data points in purple represent the standard cAMP curve, while the data point in yellow
represents the average cAMP in control cells, 3.081 ± 0.589 fmol/well, and the data point in blue represents
the average cAMP in cells treated with 1 IU BoNT-A, 8.000 ± 2.090 fmol/well. Results shown indicate the
mean ± standard deviation of OD 450 nm readings for each standard, control, and treatment.

DISCUSSION
The results of this research indicate that BoNT-A could likely be interacting with
EP4 within HSkM, but the extent and mechanisms of this interaction are still unclear
based on this data. Computational analysis suggests that BoNT-A HC and EP4 could
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have a stable interaction. While previous data demonstrates that BoNT-A may reduce
EP4 expression in the spinal cord and visceral organs (Chuang, et al., 2009), this is the
first research to propose direct molecular interactions between EP4 and BoNT-A HC. In
contrast, high total weighted scores from BoNT-A LC and COX-1, COX-2, eNOS, and
iNOS were significantly less stable. However, previous research indicates BoNT-A does
affect COX-2 in vivo (Chuang, et al., 2008; Chuang, et al., 2009), so this data could
instead imply either no interaction or a momentary, unstable interaction between these
molecules. Additionally, these molecules could be affected indirectly, which was not
investigated in this study. Finally, this data could also represent a context-dependent
interaction, in which BoNT-A may only interact with these molecules under certain
cellular conditions, such as the stress of exercise on muscle cells.
Data from the cAMP immunoassay suggests BoNT-A treatment correlates with
increased cAMP within HSkM in vitro, but more research is needed to determine the
significance of this increase, as well as whether different dilutions of BoNT-A result in
different increases of cAMP. Because upregulation of cAMP can cause hypertrophy in
skeletal muscle myofibers (Berdeax & Stewart, 2012), this data is surprising since BoNTA treatment in vivo leads to reduced hypertrophy in patients with CECS (Baria & Sellon,
2016; Isner-Horobeti, et al., 2013; Orta, et al., 2018). Furthermore, it is unclear whether
this increase is caused by activation of EP4 or by a different mechanism as cAMP is
involved with many cellular processes. Additionally, this study was limited by a small
number of experimental samples, so future research should include a greater number of
samples for clearer significance and meaning of results.
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The specific interaction of BoNT-A with EP4 is a topic of further investigation
regarding the mechanisms of BoNT-A within skeletal muscle. This could be achieved
through similar experiments in EP4 knockout mice with cAMP monitoring, as well as
experiments involving increased dosage of cAMP and symptom monitoring.
Additionally, other studies involving BoNT-A’s effects in vivo have analyzed the
expression of proteins after treatment in both the affected organs and spinal cord, as well
as in individual cell transcriptomes (Chuang, et al., 2008; Chuang, et al., 2009; Zanotti, et
al., 2018). Therefore, analysis of mRNA and spinal cord protein expression in addition to
tracking symptom management after affected skeletal muscle cells are treated with
BoNT-A may provide more insight in determining its mechanism in relation to its
therapeutic effects in treating CECS.
Finally, only normal HSkM were examined within this study. Since the
mechanisms and progression of CECS in skeletal muscle is largely misunderstood,
HSkM affected by CECS could interact with BoNT-A differently than normal HSkM.
Thus, further research should include analysis and comparison of cAMP and EP4
expression in both normal and CECS-affected HSkM in order to explore CECS and the
causes of this condition.
CONCLUSION
Overall, more data is needed to fully determine the mechanisms and effects of
BoNT-A on HSkM in vitro, especially in regards to EP4 interaction and cAMP
concentration. Most importantly, however, the data from this study indicates BoNT-A
may influence skeletal muscle cells outside of its effect at the neuromuscular junction
through novel computational evidence of EP4 and BoNT-A HC molecular interaction, as
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well as increased levels of cAMP in HSkM treated with BoNT-A, with p = 0.04 in the
one-tail t-test. Further investigation into the specific results of BoNT-A treatment on
skeletal muscle can provide valuable implications to both the uses of BoNT-A as a
treatment in a variety of diseases as well as the mechanisms of diseases such as CECS
that observe symptom reduction through therapeutic uses of BoNT-A.
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